ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,537.02
0.51%
US Tech 100
19,641.60
0.83%
Dow Jones
39,308.00
-0.06%
Brent Oil
86.525
-0.44%
Bitcoin
57,764.61
-3.99%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Chemomab Therapeutics Ltd (CMMB)

  7. Chemomab Therapeutics Ltd (CMMB) News

CMMB

Chemomab Therapeutics (CMMB)

Chemomab Therapeutics Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CMMB
DateTimeSourceHeadlineSymbolCompany
06/18/20247:00AMGlobeNewswire Inc.Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing CholangitisNASDAQ:CMMBChemomab Therapeutics Ltd
06/12/20244:02PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CMMBChemomab Therapeutics Ltd
06/06/20247:00AMGlobeNewswire Inc.Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research ConferenceNASDAQ:CMMBChemomab Therapeutics Ltd
05/17/20247:00AMGlobeNewswire Inc.Chemomab Therapeutics to Participate in Upcoming Scientific ConferencesNASDAQ:CMMBChemomab Therapeutics Ltd
05/09/20247:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CMMBChemomab Therapeutics Ltd
05/09/20247:00AMGlobeNewswire Inc.Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:CMMBChemomab Therapeutics Ltd
05/08/20247:05AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CMMBChemomab Therapeutics Ltd
05/08/20247:00AMGlobeNewswire Inc.Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RuleNASDAQ:CMMBChemomab Therapeutics Ltd
05/02/20247:00AMGlobeNewswire Inc.Chemomab Therapeutics to Present at 2024 Aegis Virtual ConferenceNASDAQ:CMMBChemomab Therapeutics Ltd
04/24/20247:00AMGlobeNewswire Inc.Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business UpdateNASDAQ:CMMBChemomab Therapeutics Ltd
04/18/20247:00AMGlobeNewswire Inc.Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic SclerosisNASDAQ:CMMBChemomab Therapeutics Ltd
04/02/20247:00AMGlobeNewswire Inc.Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024NASDAQ:CMMBChemomab Therapeutics Ltd
03/25/20247:06AMGlobeNewswire Inc.Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing CholangitisNASDAQ:CMMBChemomab Therapeutics Ltd
03/07/20247:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CMMBChemomab Therapeutics Ltd
03/07/20247:00AMPR Newswire (US)Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate UpdateNASDAQ:CMMBChemomab Therapeutics Ltd
03/05/20247:00AMPR Newswire (US)Chemomab Therapeutics to Participate in Leerink Global BioPharma ConferenceNASDAQ:CMMBChemomab Therapeutics Ltd
02/20/20249:20AMAllPennyStocks.comBiotech Shares Massively Bid Up Before Opening BellNASDAQ:CMMBChemomab Therapeutics Ltd
02/20/20247:00AMPR Newswire (US)Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory DiseasesNASDAQ:CMMBChemomab Therapeutics Ltd
02/14/20247:00AMPR Newswire (US)Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business UpdateNASDAQ:CMMBChemomab Therapeutics Ltd
02/05/20247:00AMPR Newswire (US)Chemomab Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:CMMBChemomab Therapeutics Ltd
01/30/20247:00AMPR Newswire (US)Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing CholangitisNASDAQ:CMMBChemomab Therapeutics Ltd
01/03/20247:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CMMBChemomab Therapeutics Ltd
01/03/20247:00AMPR Newswire (US)Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024NASDAQ:CMMBChemomab Therapeutics Ltd
11/16/20237:00AMPR Newswire (US)Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic SclerosisNASDAQ:CMMBChemomab Therapeutics Ltd
11/15/20234:35PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:CMMBChemomab Therapeutics Ltd
11/15/20237:00AMPR Newswire (US)Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing CholangitisNASDAQ:CMMBChemomab Therapeutics Ltd
11/13/20238:00AMPR Newswire (US)Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023NASDAQ:CMMBChemomab Therapeutics Ltd
11/09/20238:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CMMBChemomab Therapeutics Ltd
11/09/20238:00AMPR Newswire (US)Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:CMMBChemomab Therapeutics Ltd
11/06/20234:15PMPR Newswire (US)Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price RequirementNASDAQ:CMMBChemomab Therapeutics Ltd
 Showing the most relevant articles for your search:NASDAQ:CMMB

Your Recent History

USOTC
SPZI
Spooz (PK)
USOTC
CNNA
Cann American (CE)
NASDAQ
TSLA
Tesla
USOTC
KEGS
1812 Brewing (PK)
USOTC
NSAV
Net Savings Link (PK)
USOTC
SFRX
Seafarer Exploration (PK)
USOTC
NLST
Netlist (QB)
USOTC
VPLM
Voip Pal Com (QB)
COIN
BTCUSD
Bitcoin
USOTC
MGON
Megola (PK)
USOTC
ENZC
Enzolytics (PK)
USOTC
VXIT
Virexit Technologies (PK)
USOTC
BLEG
Branded Legacy (PK)
NASDAQ
COOP
Mr Cooper
USOTC
DBMM
Digital Brand Media and ... (PK)
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved